|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
LAB.PIERRE FABRE MEDICAMENT
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Acne vulgaris |
|
Hyperpigmentation, facial |
|
Wrinkles, facial |
| |
|
|
SIDE EFFECTS:
|
|
Burning or stinging sensation of skin, severe |
|
erythema, severe |
|
hypopigmentation of treated skin |
|
scaling of skin, severe |
|
unusually dry skin, severe |
|
Hyperpigmentation of treated skin |
|
Burning sensation, stinging, or tingling of skin, mild |
|
erythema, mild |
|
scaling of skin, mild |
|
unusually dry skin, mild |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Dermatitis, seborrheic |
|
>> Eczema |
|
Sensitivity to tretinoin |
|
>> Sunburn |
|
|
ADULT DOSE:
|
|
Acne vulgaris-
Initial: Topical, to the skin of affected areas, once a day at bedtime .
After the first seven to ten days of use, dose may be increased to two times a day if excessive drying of skin has not occurred .
Maintenance: Topical, to the skin of affected areas, once a day at bedtime or less often as needed .
[Keratosis follicularis] or
[Verruca plana] -
Topical, to the skin of affected areas, one or two times a day . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|